Effects of 5-HT(3) antagonism on postprandial gastric volume and symptoms in humans.

Author(s): Kuo B, Camilleri M, Burton D, Viramontes B, McKinzie S, Thomforde G, O'Connor MK, Brinkmann BH

Affiliation(s): Enteric Neuroscience Program, Gastroenterology Research Unit, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA.

Publication date & source: 2002-02, Aliment Pharmacol Ther., 16(2):225-33.

Publication type: Clinical Trial; Randomized Controlled Trial

BACKGROUND: Alosetron reduces symptoms of dyspepsia, but the physiological basis for the symptomatic benefit is unclear. AIM: To assess 5-HT3 antagonism on postprandial gastric volume and symptoms after ingestion of maximum tolerable volume of a liquid meal. METHODS: In 36 healthy volunteers, we assessed effects of placebo, 0.5 and 1 mg b.d. alosetron on fasting and postprandial gastric volumes (using single photon emission computed tomography) and symptoms based on 100 mm VAS, 30 min after maximum volume ingested. RESULTS: The 5-HT3 antagonist reduced postprandial symptoms (aggregate score: P < 0.05), nausea (P < 0.001), and tended to reduce bloating (P=0.08). Both 0.5 and 1 mg alosetron reduced nausea (P < 0.025); 1 mg alosetron reduced aggregate symptoms (P < 0.05) and bloating (P < 0.05). Effects on pain (P=0.19) and fullness (P=0.14) were not statistically significant. There were no significant effects of the 5-HT3 antagonist on volume of meal tolerated or on SPECT-measured fasting or postprandial gastric volumes. CONCLUSION: 5-HT3 antagonism reduces aggregate symptoms, nausea and bloating after a liquid meal without increase in gastric volumes, suggesting a role for 5-HT3 in afferent functions in healthy humans during the postprandial period.